Novo Nordisk Stock Slides as Eli Lilly Advances Rival Weight Loss Pill

Novo Nordisk (NVO) shares fell 2.59% on Tuesday, pressured by Eli Lilly's breakthrough in oral weight loss treatment. The rival pharmaceutical firm reported positive Phase 3 trial results for orforglipron, a pill demonstrating dual efficacy in weight reduction and blood sugar control for Type 2 diabetes patients.

The development positions Eli Lilly to challenge Novo's Wegovy, currently the dominant injectable weight loss drug in the U.S. market. With both companies racing for FDA approval of oral formulations, the competition intensifies for capturing broader patient adoption beyond injection therapies.

Market reaction reflects investor concerns about Novo's first-mover advantage eroding. The stock's 34.99% year-to-date decline underscores mounting pressure in the lucrative weight loss therapeutics sector, where delivery method innovation increasingly drives competitive positioning.